Affordable Access

An IL-7 fusion protein that shows increased thymopoietic ability.

Authors
Journal
The Journal of Immunology
0022-1767
Publisher
The American Association of Immunologists
Publication Date
Disciplines
  • Biology
  • Medicine

Abstract

The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

An IL-7 fusion protein that shows increased thymop...

on The Journal of Immunology Sep 15, 2005

A B7.1-antibody fusion protein retains antibody sp...

on The Journal of Immunology Apr 01, 1998

An IgG3-IL2 fusion protein activates complement, b...

on Immunotechnology : an internat... August 1995
More articles like this..